3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Breast
1
Conditions
Stomach Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Lung Neoplasms
1
Head and Neck Squamous Cell Cancer
1
Head and Neck Neoplasms
1
Esophageal Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Interventions
pembrolizumab
30
Nivolumab
11
atezolizumab
8
Docetaxel
8
Cisplatin
7
Carboplatin
7
Gemcitabine
6
fludarabine
5
Trastuzumab
5
Paclitaxel
5
Ipilimumab
5
Fluorouracil
5
Cyclophosphamide
5
spartalizumab
4
cemiplimab
4
avelumab
4
Polymerase Chain Reaction
4
Cetuximab
4
Capecitabine
4
Bevacizumab
4
130-nm albumin-bound paclitaxel
4
aldesleukin
3
Taxes
3
Oxaliplatin
3
Magnetic Resonance Spectroscopy
3
Leucovorin
3
Interleukin-2
3
Gene Expression Profiling
3
Drug Therapy
3
Biopsy
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Stomach Neoplasms
×
rocakinogene sifuplasmid
×
Head & Neck
×
Clear all
NCT02960594
2018-11-19
TRT-001
Inovio Pharmaceuticals
Phase 1
Completed
93 enrolled